Increased forearm bone mineral content after bromocriptine treatment in hyperprolactinemia
- 1 November 1985
- journal article
- research article
- Published by Springer Nature in Calcified Tissue International
- Vol. 37 (6) , 687-689
- https://doi.org/10.1007/bf02554932
Abstract
We studied 15 hyperprolactinemic women to evaluate possible modifications of bone mineral content after pharmacological treatment. Patients received a dopamine agonist (bromocriptine) for six months after which there was a significant decrease of prolactin plasma levels (P<0.01) and a significant increase of bone mineral content (F<0.05)This publication has 14 references indexed in Scilit:
- Bone Density in Amenorrheic Women with and without Hyperprolactinemia*Journal of Clinical Endocrinology & Metabolism, 1983
- Hypoprolactinemic Action of Calcitonin and the Tuberoinfundibular Dopaminergic SystemJournal of Neurochemistry, 1983
- Calcitonin inhibition of physiological and stimulated prolactin secretion in ratsLife Sciences, 1981
- Decrease in Serum Prolactin Levels after Acute Intravenous Injection of Salmon Calcitonin in Normal SubjectsHormone and Metabolic Research, 1981
- Decreased Bone Density in Hyperprolactinemic WomenNew England Journal of Medicine, 1980
- Role of pituitary hormones in regulating renal vitamin D metabolism in man.BMJ, 1980
- The Interrelationships among Prolactin, 1,25-Dihydroxyvitamin D, and Parathyroid Hormone in Humans*Journal of Clinical Endocrinology & Metabolism, 1979
- Failure to demonstrate stimulatory effect of prolactin on vitamin D metabolism in vitamin-D-deficient ratsMetabolism, 1979
- ProlactinNew England Journal of Medicine, 1978
- CLINICAL AND ENDOCRINE FEATURES OF HYPERPROLACTINAEMIC AMENORRHOEAClinical Endocrinology, 1976